February 21, 2013
Staying on top in a competitive world requires constant
vigilance and front-running insight and knowledge.
Therefore, we are deeply pleased to introduce the Uniferon
Iron-deficiency Expert Board: A selected group of the world's most
respected iron/growth experts.
The International Iron Expert Board was founded in 2012
and consists of:
Professor Jens Peter Nielsen, University of
Copenhagen
Professor Guy-Pierre Martineau, University of
Toulouse
Professor Tore Framstad, Norwegian School of Medicine
Senior
Project Manager Marie Erika Busch, Pig Research
Centre
Professor Robert Friendship, University of
Guelph
The purpose of the Iron-deficiency Expert Board is very
clear: To create a stronger focus on iron as a significant factor
in piglet health, especially beyond the present day use.
This is done in order to ensure adequate iron supplement
for all piglets (avoiding an "iron gap") and to understand anaemia
in general and the relation between anaemia and growth.
The Iron-deficiency Expert Board is presently working on a
poster on assessment of anaemia prophylaxis in piglets for the
European Symposium of Porcine Health Management in Edinburgh in May
2013. The group is also working on two protocols: A herd
diagnostics protocol and an optimized care protocol.
At Pharmacosmos, we are convinced that the board will
contribute significantly to the iron/growth discussion on an
international scale, while providing very tangible and hands-on
input to our continuous work in the field of injectable iron
supplementation and best practice.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.